© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The Food and Drug Administration (FDA) recently approved AbbVie’s Mavyret, the newest treatment for chronic hepatitis C.
Mavyret taken for eight weeks was well tolerated and cured all HIV-positive people without cirrhosis in a recent study
Maviret and Vosevi were highly effective and well tolerated in clinical trials.
Glecaprevir/pibrentasvir (G/P) cured high rates of those with genotype 1 who failed a previous hep C cure attempt in a Phase II study.
The single-pill regimen would provide an eight-week ribavirin-free option for those with all viral genotypes who do not have cirrhosis.
The once-daily investigational hepatitis C virus (HCV) combination tablet will likely be approved in 2017.
AbbVie’s investigational hepatitis C virus (HCV) treatment is poised for approval in 2017.
The investigational glecaprevir/pibrentasvir performed very well among the historically hard-to-treat group, including those with cirrhosis.
AbbVie’s investigational daily, fixed-dose combination tablet performed very well among those with milder liver damage.
The FDA grants breakthrough therapy designation to AbbVie’s experimental hepatitis C regimen glecaprevir/pibrentasvir
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
